EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Global epidemiology of azole resistance in Aspergillus fumigatus

Anneke Fengler, Oliver Bader, Oliver Cornely iD, Oliver Kurzai, Jacques F Meis iD, Florent Morio, Axel Hamprecht

JAC-Antimicrobial Resistance · 07.01.2026 · 8 (1)

DOI: 10.1093/jacamr/dlaf219 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift JAC-Antimicrobial Resistance, online erschienen am 12.02.2026. Verfasst von Anneke Fengler und 6 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Medical Microbiology and Virology, Carl von Ossietzky Universität Oldenburg, Oldenburg, Germany. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 192 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The fungus Aspergillus fumigatus has evolved as an important cause of opportunistic fungal diseases in humans worldwide. It is the most frequent filamentous fungus colonizing the airways of patients with cystic fibrosis and can affect immunocompetent as well as immunocompromised individuals. Aspergillus disease is commonly treated with azoles, which inhibit lanosterol 14α-demethylase, a key component of the ergosterol biosynthesis pathway, essential for membrane integrity and fluidity. Lanosterol 14α-demethylase is encoded by the CYP51A gene. Azole-resistant A. fumigatus isolates often show amino acid substitutions in Cyp51A. Most prevalent mutations have a tandem repeat (TR) in the promoter and point mutations in the gene (e.g. TR34/L98H and TR46/Y121F/T289A). In addition to TRs, isolates with single point mutations developed and are widespread around the world (e.g. M220I, G54R). To date, azole-resistant isolates have been found on every continent except Antarctica. This review will summarize the epidemiology and prevalence of Azole-resistant A. fumigatus worldwide including the history of different mutations found and highlights important gaps as data are missing in several parts of the world.

Autor:innen und Institutionen

  • Institute of Medical Microbiology and Virology, Carl von Ossietzky Universität Oldenburg, Oldenburg, Germany.
  • Institute for Medical Microbiology and Virology, University Medical Center Göttingen, Göttingen, Germany.
  • Institute of Translational Research, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), Faculty of Medicine, University of Cologne, Cologne, Germany.
  • Department of Internal Medicine, Division of Infectious Diseases, Excellence Center for Medical Mycology (ECMM), University Hospital Cologne, Cologne, Germany.
  • German Centre for Infection Research (DZIF), Partner Site Bonn-Cologne, Cologne, Germany.
  • Institute for Hygiene and Microbiology, University of Würzburg, Würzburg, Germany.

ORCID-Profile: Oliver Cornely, Jacques F Meis

Zitieren

APA

Fengler, A., Bader, O., Cornely, O., Kurzai, O., Meis, J. F., Morio, F., & Hamprecht, A. (2026). Global epidemiology of azole resistance in Aspergillus fumigatus. JAC-Antimicrobial Resistance, 8(1). https://doi.org/10.1093/jacamr/dlaf219

Vancouver

Fengler A, Bader O, Cornely O, Kurzai O, Meis JF, Morio F, et al. Global epidemiology of azole resistance in Aspergillus fumigatus. JAC-Antimicrobial Resistance. 2026;8(1). doi:10.1093/jacamr/dlaf219

BibTeX
@article{Fengler2026,
  author = {Fengler, Anneke and Bader, Oliver and Cornely, Oliver and Kurzai, Oliver and Meis, Jacques F and Morio, Florent and Hamprecht, Axel},
  title = {Global epidemiology of azole resistance in Aspergillus fumigatus},
  journal = {JAC-Antimicrobial Resistance},
  year = {2026},
  volume = {8},
  number = {1},
  doi = {10.1093/jacamr/dlaf219}
}
Kostenlos starten →